Events
PAREA Events:
All Upcoming Events
Advancing ketamine-assisted therapy: European lessons on implementation in public healthcare
Join our upcoming webinar co-organised by PAREA and Ukrainian Psychedelic Research Association, which will explore how different European countries are integrating treatment with ketamine for mental health conditions within public healthcare systems, drawing lessons that can inform efforts to expand medical access and routine use of ketamine-assisted therapy in Ukraine and beyond.
The event is officially supported by the Ukrainian Ministry of Health's Public Health Centre. Iryna Ivanchuk, Department Head at the Centre, will deliver the opening remarks.
Confirmed speakers include Lowan Stewart (Medical Director, Axonklinikken, Norway), covering Norway’s implementation of ketamine therapy in reimbursed healthcare, David Erritzoe (Director, Centre for Psychedelic Research, Imperial College London), presenting progress towards the integration of ketamine therapy in the UK’s National Health System, and Fabrice Jollant (Professor of Psychiatry, Paris-Saclay University; President, National Union for Suicide Prevention) who will be speaking about compassionate access to ketamine for suicidal crisis in France.
📅 23 September 2026 | 🕒 18:00-19:30 CEST | 19:00 – 20:30 EET
📍 Online
TAIP Conference
TAIP is the first international scientific conference on psychedelic-assisted therapy in Estonia.
It is open to mental health professionals, clinicians, researchers, students, healthcare professionals, policymakers and anyone interested in the field.
Their why? Europe is facing a mental health crisis that calls for new treatment approaches. Psychedelic-assisted therapy is a rapidly evolving field that deserves attention. We create a space for science-based discussion on innovative approaches in mental health care.
There will be insightful talks, panel discussions, expert conversations, new connections and collaboration opportunities.
Learn more about the conference and secure your ticket through the following link: https://www.sataip.ee/conference
ALPS Conference
On 9-10 October, ALPS Foundation - Awareness Lectures on Psychedelics in Switzerland, a PAREA Community Supporter, is holding the 6th edition of the ALPS Conference in Aarau, Switzerland.
Now Switzerland's largest conference dedicated to evidence-based psychedelic science and mental health, it brings together researchers, clinicians, therapists, and students from Switzerland and abroad for two days of talks, panel discussions, and research posters. The conference is convened with academic partners including the Universities of Basel, Zurich, Geneva, and Fribourg, and the Geneva University Hospitals (HUG).
The programme features around 16 speakers, including Prof. Dr. Eric Vermetten (Leiden University Medical Center), Dr. Sandeep Nayak (Johns Hopkins Center for Psychedelic and Consciousness Research), and Dr. Max Wolff (Humboldt University of Berlin), alongside researchers from the Universities of Zurich and Fribourg and traditional wisdom keeper Ricardo Morales.
This year on 8 October, there will be a dedicated pre-conference Workshop Day with four parallel psychedelic-assisted therapy training tracks in English, German, French, and Italian. Professionals can earn up to 14 federally-recognised education credit.
Early-bird tickets are available until 20 September 2026!
Explore the full programme and get your tickets here: https://alpsconference.com/
4th Symposium by Psychedelic Society Belgium
When Healing Is Not a Shortcut: Integrity in Psychedelic Therapy, the 4th Symposium by Psychedelic Society Belgium, will be taking place on October 9–10, 2026 in Brussels, this year’s symposium invites an open and thoughtful exploration of the promises, limitations, responsibilities, and ethical challenges surrounding psychedelics in mental health and society. Across one and a half days of talks, dialogue, and exchange, we will bring together researchers, therapists, clinicians, policymakers, artists, and people with lived experience to engage with one central question:
How do we support a psychedelic field rooted in integrity, humility, responsibility, and care?
As interest in psychedelic-assisted therapies continues to grow internationally, we believe it is essential to create space not only for optimism and innovation, but also for critical reflection, nuance, and harm reduction.
Explore the program, discover the speakers, and learn more about the gathering here:
SCALE 2026 Conference in Prague
SCALE takes place at a pivotal moment for the future of mental health care. Research is advancing rapidly, clinical evidence is growing, and innovative approaches, including psychedelic-assisted therapies, are gaining recognition from regulators. But evidence alone is no longer enough. The challenge now is how to translate scientific progress into real-world access. How to build effective regulatory frameworks, align research with clinical practice, and connect innovation with healthcare payers and public institutions. Ultimately, the goal is clear - to ensure that novel mental health treatments reach the patients who need them most.
SCALE brings together leading scientists, clinicians, policymakers, insurers, investors, philanthropists, and international experts to address this challenge. The conference focuses on key questions shaping the field today, from strengthening psychological resilience in times of crisis and responding to war-related trauma, to understanding global trends in psychiatric care, designing regulatory pathways, and advancing discussions on cost-effectiveness and reimbursement.
SCALE is about the next phase of mental health innovation - moving from evidence to access, and turning progress into real impact.
Explore the agenda and get your tickets here: https://www.scaleprague.eu/#Conference
KAP International Association Summit
PAREA will be at the 1st KAP International Association Summit (16–18 October, Barcelona), part of the nine-day Complete KAP Experience organised by Clínica Synaptica and dedicated to Ketamine-Assisted Psychotherapy. Communications Officer Nico Gusac will present an overview of PAREA's systems-level work to build European pathways for psychedelic-assisted care, covering the Mental Health Moonshot, regulatory advocacy, and European coordination efforts. The Summit is accredited by the Catalan Council for Continuing Education of Health Professions. PAREA community members can attend using code PAREAKAP2026 for a 15% discount on the Standard 3-Day Pass.
Secure your spot today: https://www.clinicasynaptica.com/en/kap/
The REAL Summits New York 2026
On October 22-23, PAREA will be part of THE REAL Summits New York, the global event series uniting family offices, VCs, policymakers, insurers, academics, NGOs and innovators driving mental and brain health forward with a mission to move $10 billion into mental health by 2030.
Founder Tadeusz Hawrot will moderate the session "Psychedelic Medicine in 2026: Access, Adoption & Scale", exploring how psychedelics are moving from the margins of mental health into mainstream research, clinical development and investment. The conversation will cover the most promising developments in the pipeline, evolving U.S. policy, and what it will take to bring these treatments to patients safely and at scale. The session will also feature four surprise guests.
Join us there to be part of the conversation shaping the future of psychedelic medicine. This is a great opportunity to connect with the world's most influential leaders at the vital intersection of finance and mental health.
Explore the agenda and buy your tickets here.
Mental health innovation in the European Biotech Act: closing Europe’s access and competitiveness gap
17 November 2026, 15:00-17:00
European Parliament, Brussels
Hosted by MEP Romana Jerković, S&D, Health Committee SANT Vice-Chair
Organised by PAREA and European College of Neuropsychopharmacology
Europe is facing a major mental health challenge, but mental health innovation is still too often treated as a secondary issue in health and competitiveness policy. New treatments remain limited, access is uneven, and Europe is falling behind in translating promising science into patient benefit.
The European Biotech Act is one of the EU’s key initiatives to strengthen Europe’s biotechnology and health innovation ecosystem. It aims to remove barriers that slow down the development, testing and uptake of innovative health technologies. As such, the Act could become an important tool for addressing one of Europe’s largest unmet health needs.
This event will explore why mental health innovation should be part of the Biotech Act and how the Act’s existing instruments could support responsible development and access. These include regulatory sandboxes, strategic mapping and foresight, high-impact projects, investment mechanisms, support networks, data infrastructure, and repurposing and off-patent innovation.
The discussion will also consider what makes some mental health treatments different from more conventional product pathways. This is especially relevant for complex treatments such as psychedelic therapies, where outcomes may depend not only on the product itself, but also on the conditions of administration, the patient’s mindset and treatment environment, the subjective experience during the dosing session, psychological support, professional training and safe implementation in health systems.
The event comes at an important stage in the EU policy process. The European Parliament plenary vote on the Biotech Act may take place at the turn of the year, while Member State negotiations are expected to be advancing in parallel. The discussion will therefore address both the Parliament’s work and the wider Council process.
During the event, PAREA will also launch a policy paper focused specifically on the European Biotech Act, setting out how mental health innovation can be reflected in the file and why this matters for Europe’s health innovation and competitiveness agenda.
Brain Innovation Days
The Brain Innovation Days return for their 6th edition — two days bringing together leading experts, researchers, clinicians and industry pioneers from across Europe and beyond to accelerate innovation in brain health.
Day 1 focuses on Science and Policy: positioning brain health as a European priority, exploring how to connect research to investment and market uptake, and confronting the regulatory and funding barriers holding innovation back.
Day 2 turns to Scale and Impact: tackling why world-class research struggles to translate into market success, redefining how we measure the value of brain innovation, and identifying what's needed — capital, infrastructure, trust — to move ideas from proof-of-concept to real-world reach.
Together, the programme captures what's working in European brain innovation, and what still needs to change to scale it.
Learn more and explore the programme here.
World Ayahuasca Forum
This year, the World Ayahuasca Forum will take place in Girona, Spain.
The forum is a historic dialogue space built around relationship, exchange, music, art, culture, and shared inquiry across ancestral and contemporary worlds and knowledge systems. It gathers people working across systems change, regeneration, healing, science, policy, and psychedelic medicine, alongside knowledge holders from 20 Indigenous nations.
We're glad to be supporting WAF2026 as a community partner.
Use code WAF2026 for a 10% discount on tickets. Explore the programme and secure your spot through the following link: https://www.ayahuasca2026.com/programme/
Keeping the psychedelic promise: From bench to bedside
About
Over the past two decades, psychedelic research has generated evidence of the therapeutic potential across a range of psychiatric and neurological conditions, bringing new possibilities for treatment and care. As the field continues to advance rapidly, clinical research still needs to overcome current challenges in real-world implementation of psychedelic therapy.
This symposium is organised by the clinical work group of the European funded COST Action PSY-NET, a network dedicated to collaboration and evidence-based practice of psychedelic therapy. Experts will come together to discuss the current state of the psychedelic field, providing a cross-disciplinary perspective.
The PSY-NET clinical work group focuses on pathways through which psychedelics can move from “bench to bedside”: How does psychedelic mechanistic research contribute to our understanding of its clinical action? What kind of research is needed to support safe and accessible psychedelic therapy? How can we generate evidence that is robust and clinically relevant?
Programme
14h00 – 14h30
Opening remarks: Looking back to the past decades in psychedelic research
Carolina Seybert, PhD, Champalimaud Foundation
14h30 – 15h00
Session 1: Neuroimaging protocols to enhance our understanding of neurobiological mechanisms of action of psychedelics
Miguel Castelo Branco, PhD, Universidade de Coimbra
15h00 – 15h30
Session 2: Standardizing Psychological Therapy: Training and Competency Requirements
Henrik Jungaberle, PhD, Mind Foundation
15h30 – 16h00
Coffee Break
16h00 – 16h30
Session 3: Improve the methodological rigour of psychedelic RCTs - Placebo and blinding
Lucie Berkovitch, PhD, GHU Paris Psychiatrie et Neurosciences
16h30 – 17h00
Session 4: Promotion of multicenter, standardised clinical trials and regulation
Lindsey Marwood, PhD, Compass Pathways
17h00 – 17h30
Panel discussion
Moderated by Marcelo D Mendonça, MD, PhD, Champalimaud Foundation & Co-Pi of PsyPal clinical trial
17h30 – 17h45
Closing remarks
Carolina Seybert, PhD, Champalimaud Foundation
Language
The event will be held in English.
Format
Hybrid. Please let us know if you are attending in-person or online via the registration form.
Registration
Free event, but registration is mandatory.
Register here and secure your spot.
12th Congress of the European Academy of Neurology (EAN) -Brains, Bytes & Beyond: Tech in Neurology
🧠 Experience one of the world’s most significant neurology congresses.
The European Academy of Neurology (EAN) will host its 12th annual Congress in Geneva from 27-30 June 2026, bringing together thousands of neurologists, scientists, educators, and healthcare professionals from around the world to discuss the latest developments in neurology.
As one of the largest international events dedicated to brain and neurological health, the congress fosters scientific exchange, professional growth, and cross-sector collaboration.
This year’s overarching theme is “Brains, Bytes & Beyond: Tech in Neurology”, offering several highlight sessions exploring how rapid advances in computing and artificial intelligence are reshaping clinical neurology—from restorative therapies to the core processes of clinical reasoning and decision‑making—bringing both transformative opportunities and significant challenges.
Early registration is open until 22 April.
For more information and to register visit the official website: www.ean.org/congress2026
The Interdisciplinary Conference on Psychedelic Research, ICPR 2026
The seventh edition of the Interdisciplinary Conference on Psychedelic Research, ICPR 2026, will take place June 4 to 6 in Haarlem, the Netherlands. Organized by the OPEN Foundation, it is Europe’s leading scientific conference on psychedelic research, therapy, ethics, and policy.
The program brings together over 100 interdisciplinary speakers across keynotes, panel discussions, symposia, and workshops. It creates space for exchange and collaboration among researchers, clinicians, policymakers, and professionals working across the field.
Hosted at the Philharmonie in Haarlem’s historic city center, ICPR 2026 provides a focused setting to explore new scientific findings, emerging therapeutic approaches, and the ethical, societal, and policy questions shaping the future of psychedelics.
We work with partners who share a commitment to rigorous, responsible, and interdisciplinary dialogue. Their support helps make ICPR possible and strengthens collective progress in psychedelic science.
European Association for Palliative Care World Congress, Prague
We are pleased to announce that EAPC 20th World Congress will be taking place on May 14th to 16th, in Prague. This is a global gathering, where science and collaboration come together to advance palliative care.
This year introduces a new world format designed to bring together voices from every region and across disciplines. The goal is to strengthen connections, share experience, and create a truly global space for learning while keeping high quality research at the center.
Hosted in Prague under the auspices of the Czech Medical Association, Prague’s Mayor Office, the Ministry of Health, and the First Lady of the Czech Republic, the event will raise visibility for palliative care at both professional and public levels. It will highlight current priorities, support local initiatives, and position palliative care as a global discipline.
For many professionals who cannot easily travel abroad, the congress also offers access to a major international platform. It will showcase achievements while driving new ideas, innovation, and momentum for the development of palliative care systems.
European Forum of National Psychedelic Societies
European Forum of National Psychedelic Societies
The European Forum of National Psychedelic Societies is a closed, invitation-only meeting convened by PAREA in Brussels, bringing together representatives of organisations from 25 countries working on psychedelic research, policy, and access across Europe.
The Forum aims to create a structured space for exchange, coordination, and peer learning among organisations engaged in advancing safe, regulated, and equitable access to psychedelic therapies within healthcare systems.
Focus of the meeting
The Forum will focus on two core dimensions.
The first is access. This includes early access pathways, compassionate use, rescheduling, and emerging regulatory developments across European countries.
The second is implementation and engagement. This includes advocacy strategies, working with policymakers and regulators, coalition-building, and strengthening national-level capacity to support future access.
The programme is designed to move beyond general discussions and focus on practical experience, lessons learned, and approaches that can be adapted across different national contexts.
Participation
This is a closed, invitation-only meeting bringing together a curated group of organisations aligned with PAREA’s focus on medical access through healthcare systems.
The Forum is not open for public registration.
Countries and organisations represented
The Forum brings together leaders representing organisations from 24 countries across Europe, reflecting a broad and diverse landscape of national initiatives.
Participating countries and organisations include:
Austria – Association for Psychedelic Science & Therapy Austria (APSTA)
Belgium – Psychedelic Society Belgium (PSBE)
Bulgaria – Psychedelic Society Bulgaria
Croatia – Psychedelic Research Society Croatia
Denmark – Danish Center for Psychedelic Education (CEPDA)
Estonia – Foundation for Therapeutic Advancement and Innovation with Psychedelics (SA TAIP)
Finland – Finnish Association for Psychedelic Research
France – French Psychedelic Society (Société Psychédélique Française / SPF)
Germany – German Society for Psychedelic Research and Therapy (DGPFT); MIND Foundation
Greece – Greek Psychedelic Society (Kykeon)
Hungary – Upcoming Hungarian organisation
Iceland – Icelandic Psychedelic Society - Hugvikandi
Ireland – Irish Doctors for Psychedelic Assisted Therapy (IDPAT)
Italy – Italian Society for Psychedelic Medicine (SIMEPSI); Luca Coscioni Association
Netherlands – OPEN Foundation
Norway – Norwegian Association for Psychedelic Science (NPV)
Poland – Polish Psychedelic Society; HoloMind Foundation
Portugal – Eleusis Institute
Romania – Upcoming Romanian organisation
Serbia – National Association for Psychedelic Research
Spain – inawe Foundation / Spanish Society for Psychedelic Medicine (SEMPSi)
Sweden – Swedish Network of Psychedelic Science
Switzerland – Awareness Lectures on Psychedelic Science (ALPS)
Ukraine – Ukrainian Psychedelic Research Association (UPRA)
United Kingdom – Feilding Commission
Guest speakers
The Forum will feature contributions from leading experts and practitioners who have been directly involved in advancing access and regulatory developments in Europe.
Prof. Gerhard Gründer (Germany)
Professor of Psychiatry and leading expert in neuropsychopharmacology, involved in advancing clinical research and compassionate use with psychedelic therapies in Germany.Lowan Stewart (Norway)
Clinician and key architect behind the nationwide reimbursement of ketamine treatment in Norway, with direct experience in implementing access within public healthcare systems.Pavel Bém (Czech Republic)
Physician and policy leader who has played a central role in recent rescheduling and psilocybin policy developments in the Czech Republic
Context
The Forum builds on PAREA’s ongoing work at the European level to support policy development, research, and access to psychedelic therapies, as well as its engagement with national organisations through the Community Supporters network.
It also lays the groundwork for longer-term collaboration, with the aim of strengthening coordination across countries and supporting the development of practical pathways to access in Europe.
May 6: Register now! Psychedelic research and access in Ukraine—policy discussion at the European Parliament and online
Co-organised by PAREA, the MEP Action Group on Psychedelics in Healthcare, and the Ukrainian Psychedelic Research Association (UPRA), and hosted by S&D MEP Vytenis Andriukaitis, the event will explore how evidence-based psychedelic therapies may contribute to addressing war-related mental health challenges in Ukraine, particularly PTSD among veterans.
The programme features perspectives from Ukrainian stakeholders, including veteran lived experience and a member of the Ukrainian Parliament, on the mental health burden of war and system-level needs. Following presentations will address European policy and clinical guidelines, as well as the latest evidence on MDMA-assisted therapy for PTSD and its implementation in real-world settings. We will also cover regulatory and clinical research considerations for controlled substances in mental health, with contributions from representatives of Ukraine’s State Expert Center of the Ministry of Health. The event will conclude with a panel discussion focused on aligning Ukrainian developments with European clinical and regulatory frameworks.
📅 6 May 2026 | 🕒 14:30 – 16:30
📍 European Parliament, Brussels & online (note: in-person attendance is closed)
We hope you will be able to join us for these important discussions.
Access the registration form here and view the full event agenda here!
Save the date: EU webinar on psychedelic therapy and psychological distress in palliative care
We are pleased to invite you to join an upcoming webinar on the PsyPal project, which is investigating psychedelic therapy to address psychological distress needs in palliative care, including in neurological conditions.
PAREA is co-organising this online session with the European Commission’s EU Health Policy Platform on 13 April 2026 from 14:00 to 15:30 CEST.
People living with progressive, life limiting conditions often face severe psychological and existential distress. Many health systems still lack effective ways to address these needs.
The EU funded PsyPal project is a clinical trial examining whether psilocybin-assisted therapy can reduce depressive symptoms in people living with several progressive, incurable conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), atypical Parkinsonism and advanced Parkinson's disease, and chronic obstructive pulmonary disorder (COPD).The PsyPal therapy model combines preparation, therapeutic intervention, and integration with psychotherapeutic support.
The webinar will discuss palliative care needs, emerging scientific evidence, ethical considerations in trials, and the regulatory landscape for psychedelic therapies in Europe.
SPACE Symposium, Psychedelics in the Clinic: From Science to Experience, Porto
PAREA Founder Tadeusz Hawrot will speak on Friday, April 10 at the SPACE symposium “Psychedelics in the Clinic: From Science to Experience” in Porto. His talk will focus on PAREA’s shift toward the experiential dimension of psychedelic treatments and what this means for policy and care. SPACE, a Portuguese scientific association founded in 2021, has been a PAREA Community Supporter since the early days and works to advance research and knowledge on the therapeutic use of psychedelics.
PAREA will be at the European Psychiatric Association Congress in Prague in March
Come find us at the European Psychiatric Association (EPA) Congress in Prague later this week!
The 34th edition of the EPA Congress will take place in from 28–31 March. Under the theme “Mental Health: Improving Care and Expanding Horizons”, the Congress will provide a key platform to advance clinical knowledge and explore novel mental health care approaches across Europe.
PAREA will be present with a dedicated stand in the exhibition hall, where we look forward to engaging directly with the psychiatric community on the potential and current status of psychedelic therapies. We will also be representing the EU-funded PsyPal project currently investigating psilocybin-assisted therapy to treat existential and psychological distress in palliative care settings. We are grateful to our member, the EPA, for this opportunity for meaningful exchange.
Find out more here!
Webinar: Legal and regulatory pathways for psychedelic-assisted therapies in Europe, co-organised by PAREA, UPRA and Ukraine’s Public Health Centre
This Friday, March 20, at 18:00 CET, the Public Health Centre of Ukraine and UPRA - Ukrainian Psychedelic Research Association, in partnership with PAREA, are organising an webinar on legal and regulatory frameworks for psychedelic-assisted therapies in Europe.
The discussion addresses a core challenge: how to design systems that enable research and clinical use while staying within legal boundaries. Featuring legal, regulatory, and drug policy experts João Taborda da Gama, Marion Haberkamp, and Pavel Pachta, Ph.D., this event will explore the legal frameworks shaping psychedelic therapies, the evolving research and regulatory landscape in Europe, and the impact of international Conventions on psychedelic research.
🗣️ The presentations will be in English with live interpretation into Ukrainian. These will be followed by an open discussion and Q&A.
PSYCH Symposium 2025
On Thursday, 4 December 2025 in London, PSYCH and Drug Science will host the PSYCH Symposium, a one-day gathering designed to promote the potential of psychedelics in addressing today’s mental health crisis.
The event will bring together over 400 delegates and feature leading voices in the field, including Prof. David Nutt, Prof. Sunjeev Kamboj, Dr. David Erritzoe, Prof. Celia Morgan, Dr. Louise Paterson, Dr. Anne Katrin Schlag, Dr. Grace Blest-Hopley, and many more.
PAREA will be represented by Francisca Silva, who will be sharing her expertise in psychedelic research, regulation, and access across Europe, and ensuring that patient needs and lived experience remain central to the conversation.
Learn more and register here: https://www.psychsymposium.com/
Virtual Global Launch of the WHO Guidance on Policy and Strategic Actions to Protect and Promote Mental Health Across Government Sectors
We are pleased to share an invitation to the Virtual Global Launch of the WHO Guidance on Policy and Strategic Actions to Protect and Promote Mental Health Across Government Sectors, taking place on Tuesday, 25 November 2025, from 13:00 to 14:30 CET. See draft programme attached here.
For the first time, WHO has set out concrete policy directives and strategic actions to protect and promote mental health across government sectors. The guidance covers 10 sectors - from education, justice and employment to housing, environment and interior - helping countries embed mental health in national policies and plans of these sectors, address the social and structural drivers that shape mental health, and put participation, equity and human rights at the centre of government policy and strategies.
The 90-minute event will include:
An introduction to the guidance and its rationale
Reflections from senior government representatives and stakeholders across sectors
Discussion on how each sector - and government as a whole - can apply the guidance to advance effective, equitable, and sustainable approaches to mental health
Register now to join us: https://who.zoom.us/webinar/register/WN_pkStl_5lStKeWF_mochqpA
Please share this invitation and programme widely, particularly with stakeholders from all sectors.
Psychedelic Lived Experiences Summit, November
PAREA is happy to support the Psychedelic Lived Experiences Summit, an online gathering that bridges science and lived expertise with nuance and wisdom.
📅 November 21–23, 2025
🎙️ 50+ speakers | 3 days | fully online
Psychedelic treatments are often framed as breakthroughs—but outcomes vary. This summit places lived experience at the center, inviting patients, trial participants, therapists, and researchers to share real‑world stories of healing, difficulty, and everything in between. Expect streamed interviews, live Q&As, and interactive sessions that move beyond hype and fear toward safety, ethics, inclusion, and realistic expectations.
When we start by listening to the people these treatments are meant to help, clinical science, practice, and policy all get smarter—and care gets safer.
We’re honored to stand alongside fellow supporting partners including OPEN Foundation, California Institute of Integral Studies (CIIS), PsyPAN, Psychedelic Alpha, Psychedelic Association of Canada, TheraPsil, Fireside Project, ACER Integration, and Blossom.
Learn more and register here: https://psychedeliclivedexperiences.com/summit
HoloMind: Psychedelic Therapy and Integration Conference
The Psychedelic Therapy and Integration Conference aims to scientifically and comprehensively integrate knowledge and research on the use of psychoactive substances in treating conditions such as treatment-resistant depression, post-traumatic stress disorder (PTSD), and addiction. The therapeutic application of psychoactive substances is gaining a growing following among scientists and therapists worldwide. It is already legal in the USA (Oregon), Australia, and Israel and the process of decriminalization has already started in the Netherlands. The therapeutic potential of such treatments is also being considered by the European Parliament.
HoloMind seeks to inform attendees about the latest methods for treating depression and PTSD, while also promoting harm reduction associated with the illegal use of psychoactive substances as part of our educational mission.
Learn more and register here.
UW Madison Psychedelic Symposium, Nov 13-14
The University of Wisconsin Madison Transdisciplinary Center for Research in Psychoactive Substances will hold the fifth annual Psychedelic Symposium November 13-14, 2025.
The 2025 UW-Madison Psychedelic Symposium is a dynamic and transdisciplinary event aimed at expanding awareness, fostering knowledge exchange, and bridging gaps in psychedelic research, education, and policy. The symposium will bring together researchers, graduate students, and key industry stakeholders to share knowledge and facilitate collaboration.
The term “reset” can have many different meanings, depending on the context. Traditionally, it has meant a restart, often with the goal of correcting or improving a thing or action. More broadly, reset has been used to help conceptualize technology — such as restoring a device — back to its original state, while concepts like the “The Great Reset” have described large-scale economic and societal shifts. Psychedelic science and therapy have hypothesized various kinds of resets, relating to how substances and integration might help people break out of rigid thought patterns, alleviating issues like intractable depression, anxiety, or PTSD. In the realm of wellness or psychology, reset has often referred to a mental or emotional refresh and has been associated with reevaluating behavior, changing habits, or taking a break. In 2025, reset is also a useful way to think about the psychedelic field itself.
Learn more and register here.
NEXUS
NEXUS (Neuroscience Experts and Cross-Sector Unconventional Stakeholders) aspires to bring insights, new findings, and potential solutions to the front lines of mental health that acknowledge the connection between trauma and mental health. NEXUS strives to foster understanding, resilience, and healing for underserved communities and anyone else who has been impacted by trauma.
Through education, support, and advocacy, we aim to empower individuals and communities to thrive beyond their trauma.
From Lagging to Leading: Mental Health Innovation “Made in Europe”
Europe is at a crossroads. Mental health conditions now cause more years of ill-health than cancer, diabetes, and cardiovascular disease combined, yet psychiatric innovation has stagnated, leaving patients dependent on treatments first developed half a century ago. This neglect is not only a public health failure but also a competitiveness challenge, as Europe falls behind the US and China in life sciences investment and clinical innovation. This event will explore how Europe can move from leading to lagging in mental health innovation.
With the right policies, Europe can close the innovation gap and ensure that patients gain timely access to new treatments. A mental health “moonshot” and a coordinated EU Mental Health Strategy should mobilise funding, set ambitious goals, and provide long-term direction. Stronger incentives for high-risk and cross-sector research are needed to unlock breakthroughs where market forces alone have failed. The modernisation of regulatory frameworks must ensure that innovative combination therapies can be properly evaluated. And greater investment in infrastructure and workforce capacity is essential so that health systems are ready to deliver the next generation of treatments.
The use of novel tools such as regulatory sandboxes, to be introduced in the EU pharma reform, can enhance the responsible translation of science into care. By allowing controlled, real-world testing of innovative treatments, sandboxes can both generate crucial evidence for regulators and payers and provide safe, early access for patients. Psychedelic therapies, now in late-stage development, provide an ideal test case for how sandboxes can help bridge the gap between clinical trials and health system integration.
By taking decisive action, Europe can elevate mental health as a driver of innovation and competitiveness and turn today’s crisis into tomorrow’s success story.
IDPAT Conference
This fall, PAREA will participate in the IMBAS Psychedelic Research Conference, co-hosted by IDPAT and the Trinity College Dublin Psychedelic Research Group.
IDPAT is a non-profit organisation dedicated to increasing awareness of psychedelic research among clinicians and policymakers in Ireland. It brings together doctors, researchers, psychotherapists, and healthcare professionals working across a broad range of specialties, from general practice to psychiatry, neurology to oncology. They believe that many patients in Ireland would benefit from access to psychedelic-assisted therapy and advocate for it to become a publicly available and reimbursed treatment. They also advocate for patient access to state-funded psychedelic research trials.
We will be represented by our Project Officer, Francisca Silva, who is scheduled to speak on Friday at 2:00 PM. Her session will be followed by a 1-hour panel discussion at 4:30 PM, featuring: David Erritzoe, James Rucker, Liam Modlin, Celia Morgan, and Professor David Nutt.
We’re looking forward to meaningful dialogue, knowledge exchange, community building and to connecting with those of you who’ll be joining.
Find out more about IDPAT: https://www.idpat.ie/
ALPS Research Conference
Awareness Research on Psychedelic Science
The ALPS Foundation is delighted to invite you to the fifth edition of the ALPS Awareness Lectures on Psychedelic Science, taking place on Friday and Saturday, October 24–25, 2025, at Campus Biotech in Geneva, Switzerland.
Campus Biotech, a leading center for neuroscience and biotechnology, offers an inspiring setting for two full days of cutting-edge science, meaningful dialogue, and community building. The conference will be held in english.
Participants can earn up to 14 continuing education credits, accredited by FSP and SGPP for psychologists and medical professionals.
Brain Innovation Days
Brain Innovation Days Return to Brussels in October 2025
The 5th edition of the Brain Innovation Days will take place on 15–16 October 2025 at La Tricoterie in Brussels. This two-day event brings together the wider brain health and research community to foster collaboration and accelerate innovation across the brain ecosystem.
This year’s theme, “The Adaptive Brain in a Fast-Evolving World,” will guide discussions across four key subthemes:
Brain Research Frontiers: Driving Europe’s Innovation Leadership
Brain Health Equity: Closing the Gap to Leave No One Behind
Youth Culture: Shaping Brain Health in the Modern World
Beyond Neuroscience: Reimagining the World Through a Brain Health Lens
The event is expected to gather researchers, clinicians, policymakers, and industry leaders from across Europe and beyond.
More details can be found on the official event page.
LAPsyConf: the international conference on the new health ecosystem
For the first time, Buenos Aires will host LaPsyConf: an international conference on mental health, longevity, and emerging therapeutics. We are proud to announce that Tadeusz Hawrot, Founder of PAREA, will deliver the opening address on Day 1 (October 8).
His talk, “Global Issues: Mental Health Indicators, Global Regulation, and Economic Impact,” will set the stage for three days of dialogue among global leaders in science, policy, and innovation. Drawing on his experience working with the World Health Organization and the European Union, Tadeusz will provide a global perspective on how regulation, health data, and economics are shaping the future of mental healthcare.
LaPsyConf will take place October 8–10, 2025, bringing together more than 20 world-renowned experts, including Rick Doblin, Professor David Nutt, Spencer Hawkswell, Chris Timmermann, and Bia Labate, Ph.D.
The program will feature masterclasses, open panels, immersive experiences, a startup demo day, and networking opportunities for clinicians, regulators, investors, researchers, and the general public. The goal is to explore evidence-based, ethical, and sustainable solutions to the global mental health crisis, with a focus on psychedelics, neuroscience, medicinal plants, and longevity science.
As Media Partner, PAREA is proud to support this important initiative. Our community receives a 10% discount on tickets for both the Masterclasses (October 9) and the Open Conference (October 10) with the code PAREA.
Find out more and register here: www.lapsyconf.com
Inawe Foundation for Psymposium Madrid 2025
PAREA is proud to partner with Inawe Foundation, organizer of Psymposium Madrid 2025, which will take place at the Illustrious College of Physicians of Madrid from October 2–4, 2025.
This international conference will bring together experts, researchers, and professionals from diverse disciplines to discuss innovation in mental health, neuroscience, and psychedelics. The program emphasizes combining science, technology, and the humanities to move toward therapeutic models that are more accessible, integrative, and effective.
This year’s program features a strong lineup of international speakers. Among them are Dr. David Erritzøe, Dr. José Carlos Bouso, Dr. Liliana Galindo, Dr. Christopher Timmerman, Dr. Óscar Soto, Marc Aixalá, and others. The majority of interventions will be in Spanish, with simultaneous translation into English available.
As part of this collaboration, the PAREA community will benefit from a 10% discount on tickets with the code PSYMP0S1UM2025.
The 3rd Finnish Interdisciplinary Conference: Psykedeelit 2025: Challenging Psychedelics,
On October 2–4, 2025, Psyty will host the third Finnish Interdisciplinary Conference — Psykedeelit 2025: Challenging Psychedelics. This year’s edition focuses on discussing problems, offering alternative perspectives, and challenging established notions in psychedelic research related to methodology, philosophy, and ethics.
🗓 October 2–4, 2025
📍 Åbo Akademi University, Turku, Finland
🎯 Theme: Challenging Psychedelics — advancing methodological rigor, ethics, decolonizing knowledge, and researcher objectivity across the field.
Keynote speakers include:
• Michiel van Elk (Leiden University) — methodological questions in psychedelic research
• Christine Hauskeller (University of Exeter) — decolonization in psychedelic science
• Daniel Villiger (Uehiro Oxford Institute, University of Oxford) — (bio)ethical issues in psychedelic-assisted therapy
Explore the programme and register here: https://lnkd.in/dz4xUNhK
Psychedelic Therapy: From Evidence to Equity
On October 1st, PAREA will be attending Psychedelic Therapy: From Evidence to Equity, a one-day symposium hosted by the Champalimaud Foundation.
Held just after the PsyPal General Assembly, the event will gather clinicians, researchers, patient representatives, policymakers, and ethicists to explore the development of psychedelic-assisted care in Europe, framed by the four pillars of medical ethics: beneficence, autonomy, non-maleficence, and justice. Speakers include representatives from EU institutions, regulatory agencies, civil society, and leading research groups.
Check out the impressive lineup and register for the symposium here: https://lnkd.in/d5S3u3DG
Borealis Psychedelic Science Summit
We’re pleased to support the upcoming Borealis Psychedelic Science Summit, a two-day scientific conference taking place in Stockholm on September 26–27, as a Community Partner.
The event will bring together researchers, clinicians, policymakers, and students to discuss the latest developments in psychedelic research, mental health, neuroscience, ethics, and healthcare integration.
PAREA’s Tadeusz Hawrot will also be attending the summit.
PAREA community can benefit from a 15% discount using the code PAREA15.
Learn more and register here: https://borealissummit.com
European Parliament event with PsychedeliCare: “Unlocking the potential of Psychedelic-Assisted Therapies for Europe’s Mental Health crisis”
Our first gathering at the European Parliament of the year in partnership with PsychedeliCare, marking the launch of their European Citizen’s Iniative campaign and the re-restablishment of PAREA’s MEP Action Group on Psychedelic in Healthcare. We will discuss the current state of scientific research and emphasise real-world lived experiences with psychedelic therapies, showcasing a call to action for European innovation in this important area.
Pathways To Access Summit
We are delighted to be a co-organiser of the Pathways to Access Summit in The Netherlands in June. Our founder Tadeusz is also speaking at the event. This will be a full day of insightful exploration of the opportunities and challenges around the development, approval and eventual integration of psychedelic medicines ino mainstream European health care.
Launching PsyPal: Pioneering psilocybin-assisted therapy in palliative care
We are pleased to invite you to the launch event of the PsyPal project, funded by the European Union, exploring the use of psilocybin in palliative care. The event will take place at the European Parliament in Brussels, kindly hosted by MEP Cyrus Engerer on 9th April from 12:15 to 13:45. It will be held under the auspices of the MEP Interest Group on Brain Health and Neurological Conditions and the MEP Action Group for the Medical Use of Psychedelics.
Innovating mental Health in the EU Pharma Legislation: Regulatory Pathways for Psychedelic Therapies
On behalf of the MEP Action Group for the Medical Use of Psychedelics, we warmly invite you to an event at the European Parliament, focusing on the potential of psychedelic therapies within the evolving EU pharma legislation context. This event marks the first meeting organized under the umbrella of the recently formed MEP Action Group. The key focus of the meeting will be on discussing the creation of a supportive regulatory environment to stimulate innovation in novel mental health treatments, particularly in the promising field of psychedelic therapies.
REGISTRATION REQUIRED